Veradigm Inc. (NASDAQ:MDRX) Shares Sold by Comerica Bank

Comerica Bank decreased its holdings in Veradigm Inc. (NASDAQ:MDRXGet Rating) by 9.8% in the third quarter, Holdings Channel reports. The firm owned 105,544 shares of the software maker’s stock after selling 11,460 shares during the period. Comerica Bank’s holdings in Veradigm were worth $1,511,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC boosted its position in shares of Veradigm by 578.4% in the 3rd quarter. CWM LLC now owns 2,103 shares of the software maker’s stock worth $32,000 after purchasing an additional 1,793 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Veradigm in the 3rd quarter worth $93,000. Ritholtz Wealth Management acquired a new stake in shares of Veradigm in the 3rd quarter worth $158,000. MQS Management LLC acquired a new stake in shares of Veradigm in the 2nd quarter worth $154,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Veradigm in the 2nd quarter worth $156,000. Institutional investors and hedge funds own 99.76% of the company’s stock.

Insider Activity at Veradigm

In related news, CEO Richard J. Poulton sold 10,000 shares of Veradigm stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $18.14, for a total value of $181,400.00. Following the completion of the transaction, the chief executive officer now owns 722,517 shares in the company, valued at approximately $13,106,458.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Veradigm news, SVP Tejal Vakharia sold 8,642 shares of the business’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $18.42, for a total transaction of $159,185.64. Following the completion of the sale, the senior vice president now directly owns 222,604 shares in the company, valued at approximately $4,100,365.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Richard J. Poulton sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $18.14, for a total value of $181,400.00. Following the sale, the chief executive officer now owns 722,517 shares of the company’s stock, valued at $13,106,458.38. The disclosure for this sale can be found here. Insiders sold a total of 61,776 shares of company stock worth $1,137,271 in the last 90 days. Corporate insiders own 2.29% of the company’s stock.

Veradigm Stock Performance

Shares of MDRX stock opened at $18.50 on Monday. The stock has a market cap of $2.02 billion, a PE ratio of 43.02, a price-to-earnings-growth ratio of 1.54 and a beta of 1.01. The business has a 50-day simple moving average of $18.26 and a 200-day simple moving average of $16.71. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.17. Veradigm Inc. has a 52-week low of $13.59 and a 52-week high of $23.25.

Veradigm (NASDAQ:MDRXGet Rating) last issued its quarterly earnings data on Thursday, November 3rd. The software maker reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.05. Veradigm had a return on equity of 10.74% and a net margin of 7.25%. The business had revenue of $151.90 million during the quarter, compared to analysts’ expectations of $152.79 million. During the same quarter in the previous year, the firm posted $0.21 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, equities analysts expect that Veradigm Inc. will post 0.68 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the company. TheStreet raised Veradigm from a “c+” rating to a “b-” rating in a research report on Wednesday, November 30th. The Goldman Sachs Group raised Veradigm from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $22.00 to $23.00 in a research report on Tuesday, November 8th. JPMorgan Chase & Co. lifted their price target on Veradigm from $19.00 to $20.00 and gave the stock an “underweight” rating in a research report on Friday, November 18th. StockNews.com assumed coverage on Veradigm in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $17.00 price target on shares of Veradigm in a research report on Friday, November 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.67.

Veradigm Company Profile

(Get Rating)

Allscripts Healthcare Solutions, Inc, together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

Featured Articles

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veradigm Inc. (NASDAQ:MDRXGet Rating).

Institutional Ownership by Quarter for Veradigm (NASDAQ:MDRX)

Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.